Navigation Links
Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
Date:2/19/2008

ognostic and pharmacogenomic evaluations in their updated treatment guidelines.

Targeted Agents in Combination are Entering Clinical Trials

The validated association of aggressive disease and the overexpression of HEr2 in any type or stage of breast cancer have created a $4 billion global market for trastuzumab (Herceptin; Genentech) in 2007. Still, nearly 50% of HEr2-positive patients do not respond to trastuzumab, and survival benefits are transient, often lasting under a year. Furthermore, side effects remain a significant problem. Despite these limitations, trastuzumab is the standard of treatment for both early stage and advanced or metastatic disease and is undergoing clinical trials in combination with numerous approved or novel anticancer agents.

Hundreds of clinical trials are underway combining approved targeted therapeutics with every applicable cytotoxic(s) with the goal of achieving incremental benefits. The greater opportunity, however, may lie in combining targeted therapeutics that address different points in one pathway or interacting pathways involved in angiogenesis, metastasis, drug resistance, and tumor growth and survival. This approach has entered the clinic; recently initiated trials are testing combinations of approved targeted therapeutics with each other. The full impact of combining target agents, however, will not be measured until approved and novel agents are combined in hundreds of different combinations for the treatment of hundreds of specific cancer indications.

Future Oncology Series Details ErbB Pathway-targeted Therapeutics

To date, ErbB pathway abnormalities, which occur in a large number of malignancies, have been the most extensively targeted. Currently, there are 7 approved agents targeting this pathway and over 620 clinical trials are ongoing with these agents in various combinations, mostly with cytotoxic agents but also with each other and with selected novel agents under clinical develo
'/>"/>

SOURCE New Medicine, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Preliminary PI-88 Phase 2 Prostate Cancer Results to be Presented at the American Society for Clinical Oncology (ASCO) 2008 Genitourinary Cancer Symposium
2. IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
3. US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer Symposium
4. Pharsight Uses FDA Disease Model to Support Oncology Drug Development
5. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
6. University of Pennsylvania School of Medicine Study Shows Significant Differences in English- and Spanish-speakers Use of Oncology Websites
7. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
8. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
9. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
10. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
11. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014 InfinityQS International, ... Manufacturing Intelligence , today announces Infusion Chicago, ... event will be held Oct. 9-10, 2014, at ... designed to showcase the necessity for implementing a ... and Manufacturing Intelligence to gain insight into production ...
(Date:8/21/2014)... 2014  AliveCor, Inc. announced today that ... has granted the company clearance for its ... most common form of cardiac arrhythmia. AliveCor,s ... patients are experiencing AFib through real-time electrocardiogram ... based AliveCor® Heart Monitor, so physicians can ...
(Date:8/21/2014)... N.Y. , Aug. 21, 2014  The board ... ), a leading provider of clinical trial imaging solutions, ... been named chief financial officer, effective immediately.  Mr. Groff ... since August 2013.  He joined VirtualScopics in January 2006 ... in February 2013. "When the board of ...
Breaking Medicine Technology:InfinityQS to Host Manufacturing Intelligence Conference in Chicago 2AliveCor Receives First FDA Clearance to Detect a Serious Heart Condition in an ECG on a Mobile Device 2VirtualScopics, Inc. Names James Groff Chief Financial Officer 2VirtualScopics, Inc. Names James Groff Chief Financial Officer 3VirtualScopics, Inc. Names James Groff Chief Financial Officer 4
... Inc.,(Amex: CUR ) today announced that it ... Clinic pertaining to Targeted Spinal Cord,Therapeutics Delivery. All ... formerly of Cleveland Clinic, now at Emory University., ... are very pleased to have licensed-in these important ...
... today,announced the Company,s lead product, amadacycline, formerly PTK 0796, ... Breaker,poster presentation at the 48th Interscience Conference on Antimicrobial,Agents ... D.C.,from October 25 - October 28, 2008., More ... Sunday, October 26, 12:15 - 1:15 pm EST ...
Cached Medicine Technology:Neuralstem Licenses Cleveland Clinic Spinal Cord Injection Technology 2Neuralstem Licenses Cleveland Clinic Spinal Cord Injection Technology 3Paratek to Present Clinical Data in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 2
(Date:8/22/2014)... For the first time an oncogenic somatic mutation ... transfection) protein has been identified in small cell lung ... within SCLC cell lines produced increased intracellular signaling and ... of lung cancer representing 15% of all lung cancers ... 85% of lung cancer, has been extensively examined for ...
(Date:8/22/2014)... 2014 Paying tuition and other related ... coming year for four nurse educators pursuing advanced degrees, ... for Nursing Foundation for Nursing Education . This year’s ... $10,000 more than in 2013, thanks to these named ... Elizabeth Isaac Marcil Endowment Funds, both donated by Kathy ...
(Date:8/22/2014)... New York, New York (PRWEB) August 22, 2014 ... ) continue to be filed in U.S. courts ... cardiovascular events due to their use of prescription ... to court documents, a new claim was filed ... California man who allegedly suffered life-threatening heart issues ...
(Date:8/22/2014)... 2014 CarePoint Health is proud ... Medicine, Geriatrics, Hospice and Palliative Care, Dr. Michelle ... Group. Their system welcomes Dr. Reisner to the ... comprise CarePoint Health Medical Group, a comprehensive network ... representing a wide range of specialties. This latest ...
(Date:8/22/2014)... FRIDAY, Aug. 22, 2014 (HealthDay News) -- Back-to-school time ... plan that fits into the family schedules, an expert ... a child,s school year can also be the start ... Karin Richards, a professor of kinesiology at the University ... news release. With kids, extracurricular activities likely to ...
Breaking Medicine News(10 mins):Health News:Novel oncogenic RET mutation found in small cell lung cancer 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 4Health News:Dr. Reisner Joins CarePoint Health Medical Group 2Health News:With Kids in School, Parents Can Work Out 2
... new study shows anemia may double the risk of ... erode the ability to live independently. Researchers say seniors ... are just above the traditional cut-off point for the ... declines than those who have normal blood hemoglobin levels.// ...
... than 2 million people worldwide and is caused by abnormal ... in seizures. More than half of those with epilepsy can ... is under way to determine just how effective surgery is ... epilepsy, //the most common form of the disorder.,Typically, about 80 ...
... today, be careful how much fluid you drink. Too much ... fatal outcome. ,The warning follows reports of several deaths from ... excessive drinking known as hyponatremic encephalopathy. Since the cause of ... Science Institute of South Africa, says it is preventable.,// ...
... low in saturated fats can lower bad cholesterol as effectively ... medication-free cholesterol control may be viable for some people. Researchers ... in okra, eggplant, soy proteins, oatmeal //and almonds resulted in ... just one month. ,Participants on a low-fat diet ...
... through activities such as reading, doing puzzles or playing ... cognitive abilities as you age. ,That's the message from ... of the New England Journal of Medicine. ,Researchers from ... found seniors who participated in mind-stimulating leisure activities had ...
... - When HIV-infected patients alternated their drug regimen ... longer than when one regimen was administered continuously. ... Therapy Combination against HIV-1) study. Dr. Javier Martinez-Picado, ... Spain, and others examined this alternating strategy among ...
Cached Medicine News:
... Graham-Field has been developing ... than 58 years. Our medical-surgical ... reputation for innovation, quality and ... brands include the Labtron® line ...
... Air Entrainment Nebulizers deliver particulate humidity in ... your chronic secretion patients. For your convenience, ... existing supply of sterile water., ,The ... FiO2's of 20-50% with a total flow ...
... metered dose inhalers., ,ACE ensures prompt, ... canisters. Its versatile design allows it to ... conjunction with an endotracheal airway or resuscitation ... may also be used in conjunction with ...
... Airial Handheld Ultrasonic Nebulizer has ... This compact, portable, and lightweight ... fast & quite treatments operating ... or DC auto adapter. , ...
Medicine Products: